Abstract: An ink container usable with an image forming apparatus having a carriage to transport the ink container in a reciprocating motion across a substrate and an ink ejector to eject the ink onto the substrate is included. The ink container includes a chamber configured to supply ink to the ink ejector of the image forming apparatus. The ink container also includes a separation member disposed within the chamber configured to separate unwanted particles from the ink in response to the reciprocating motion of the carriage and gravity, and to direct the ink downstream to the ink ejector.

Abstract: An ink container usable with an image forming apparatus having a carriage to transport the ink container in a reciprocating motion across a substrate and an ink ejector to eject the ink onto the substrate is included. The ink container includes a chamber configured to supply ink to the ink ejector of the image forming apparatus. The ink container also includes a separation member disposed within the chamber configured to separate unwanted particles from the ink in response to the reciprocating motion of the carriage and gravity, and to direct the ink downstream to the ink ejector.

Abstract: A method of treating non-small cell lung cancer (NSCLC), and especially NSCLC that has metastasized to brain is disclosed.

Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions that are responsive to disruption of the vascular system, and in particular to its use in treating vascular macular degeneration.

Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a cytotoxic agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating brain cancer.

Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating cancer.

Abstract: In general, the invention relates to a pharmaceutical dose having (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride as the active ingredient that upon administration to a subject provides a Cmax of about 1 ng/mL to about 250 ng/mL. The dose may be used in methods of treating cancer through the administration of (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.

Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a cytotoxic agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating melanoma.

Abstract: The invention relates to the treatment of psychiatric disorders.

Abstract: The invention relates to methods of treating or slowing the onset of overactive bladder or urinary incontinence, or a symptom thereof selected from urinary frequency, urinary urgency, nocturia, or enuresis comprising identifying and administering to a subject in need of treatment a therapeutically effective amount of a compound according to Formulae I-V, as defined herein.

Abstract: A method of treating, preventing or ameliorating one or more symptoms associated with hepatitis C virus (HCV) in a patient in whom either the HCV is of Genotype 1 and/or the patient was previously treated with interferon and the previous interferon therapy was ineffective to treat the one or more symptoms associated with HCV, comprising administering to such a patient an effective amount of at least one compound of formulae I-XXVI of which the following structural formula is exemplary or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated.